Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Race and pruritus create cancer risk picture

Kwatra SG et al. J Am Acad Dermatol. 2018 Sep 11. doi: 10.1016/j.jaad.2018.08.044.

Publish date:: September 28, 2018

Key clinical point: A wide variety of malignancies are associated with pruritus, and incidence may vary by race.

Major finding: Blacks with pruritus had higher odds ratios for hematologic and soft tissue malignancies, while whites had higher ORs for skin and liver malignancies.

Study details: A retrospective study of 16,925 adults with itching or pruritus seen at a tertiary care center.

Disclosures: Dr. Kwatra reported serving as an advisory board member for Menlo Therapeutics and Trevi Therapeutics.

Read the article.

Citation:

Kwatra SG et al. J Am Acad Dermatol. 2018 Sep 11. doi: 10.1016/j.jaad.2018.08.044.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,